- Products
- Reproduction
- Molecular diagnostics
- Careers
- About us
- Contacts
DigitalMLPA is a patented technology of MRC Holland that combines the advantages of classic MLPA methodology and Next-generation sequencing.
Enables reliable and efficient CNV analysis through 1172 probes.
The evaluation of the results is made possible by the unique Coffalyser digitalMLPA software
Principle of the method: https://support.mrcholland.com/kb/articles/video-what-is-digitalmlpa
NXtec D002-A1 Hereditary Cancer Panel 2 targets genes associated with a broad range of cancer types, such as neurofibromatoses, retinoblastoma, Wilms’ tumour, and many others, while retaining all the coverage of D001 which targets genes associated with 8 common cancer types – breast, ovarian, colorectal, gastric, prostate, pancreatic or endometrial cancer, and melanoma.
The probemix is an extension of NXtec D001-D1 Hereditary Cancer Panel 1 plus additional 26 genes (56 genes in total) and 3 target variants (8 variants in total).
The probemix consists of 1172 probes, including 1021 probes for 56 genes associated with hereditary cancer (of which 3 probes detect the wild-type allele of mutations in PMS2, POLE and BRCA2), and 10 probes for mutations in MSH2, MITF, PMS2, FLCN, HOXB13, and CHEK2.
The kit is compatible with Illumina sequencers and is intended for research use only (RUO).
Actual product information and documents can be found on the MRC Holland website.
For more information, please contact us by e-mail: diagnostika@pentagen.cz
